Human Cytomegalovirus Infection disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: HMN047 MIFTS: 53	Human Cytomegalovirus Infection Categories: Infectious diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Symptoms & Phenotypes Drugs Expand all tables

Sources

Aliases & Classifications for Human Cytomegalovirus Infection

MalaCards integrated aliases for Human Cytomegalovirus Infection:

IMPROVED

Name: Human Cytomegalovirus Infection ¹¹ ¹⁴

Cytomegalovirus Infection ²⁸ ² ¹⁶

Cytomegalovirus Infections ⁴¹ ⁷¹

Classifications:

MalaCards categories:
Global: Infectious diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:0080827

EFO ¹⁶ EFO_0001062

UMLS ⁷¹ C0010823

Sources

Summaries for Human Cytomegalovirus Infection

MedlinePlus: ⁴¹ Cytomegalovirus (CMV) is a virus found around the world. It is related to the viruses that cause chickenpox and infectious mononucleosis (mono). Between 50% and 80% of adults in the United States have had a CMV infection by age 40. Once CMV is in a person's body, it stays there for life. CMV is spread through close contact with body fluids. Most people with CMV don't get sick and don't know that they've been infected. But infection with the virus can be serious in babies and people with weak immune systems. If a woman gets CMV when she is pregnant, she can pass it on to her baby. Usually the babies do not have health problems. But some babies can develop lifelong disabilities. A blood test can tell whether a person has ever been infected with CMV. Most people with CMV don't need treatment. If you have a weakened immune system, your doctor may prescribe antiviral medicine. Good hygiene, including proper hand washing, may help prevent infections. Centers for Disease Control and Prevention

MalaCards based summary: Human Cytomegalovirus Infection, also known as cytomegalovirus infection, is related to toxoplasmosis and colitis, and has symptoms including fever and pruritus. An important gene associated with Human Cytomegalovirus Infection is PML (PML Nuclear Body Scaffold), and among its related pathways/superpathways are Innate Immune System and MIF Mediated Glucocorticoid Regulation. The drugs Prednisone and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include t cells, bone marrow and kidney, and related phenotypes are nervous system and no phenotypic analysis

CDC: ² Cytomegalovirus (pronounced sy-toe-MEG-a-low-vy-rus), or CMV, is a common virus that infects people of all ages. Over half of adults by age 40 have been infected with CMV. Most people infected with CMV show no signs or symptoms. When a baby is born with cytomegalovirus (CMV) infection, it is called congenital CMV. About one out of every 200 babies is born with congenital CMV infection. About one in five babies with congenital CMV infection will have long-term health problems.

Disease Ontology: ¹¹ A viral infectious disease that has material basis in Human betaherpesvirus 5.

Sources

Related Diseases for Human Cytomegalovirus Infection

Diseases related to Human Cytomegalovirus Infection via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1464)

#	Related Disease	Score	Top Affiliating Genes
1	toxoplasmosis	31.2	TNF IL6 IL17A
2	colitis	31.1	TNF IL6 IL17A CD4 CCR6
3	chorioretinitis	30.9	TNF IL6 IL17A CD8A CD4 CCR6
4	gastritis	30.9	TNF IL6 IL17A CCR6
5	esophagitis	30.8	TNF IL6 EGFR
6	bronchiolitis	30.8	TNF IL6 IL17A
7	bronchiolitis obliterans	30.8	TNF IL6 IL17A
8	rubella	30.8	TNF IL6 IFNB1
9	adult t-cell leukemia/lymphoma	30.7	CD8A CD4 CCR6
10	cystitis	30.7	TNF IL6 IL17A
11	encephalitis	30.7	TNF RSAD2 IL6 IFNB1
12	bilirubin metabolic disorder	30.7	TNF IL6 CD8A CD4
13	pneumocystosis	30.6	TNF IL6 IL17A CD8A CD4 CCR6
14	congenital toxoplasmosis	30.6	TNF CD8A CD4
15	deficiency anemia	30.6	TNF IL6 CD8A CD4 CCR6
16	purpura	30.6	TNF IL6 IL17A
17	granulomatous hepatitis	30.6	TNF CD8A CD4
18	pericardial effusion	30.5	TNF IL6 CD4
19	hemophagocytic lymphohistiocytosis	30.5	TNF IL6 CD8A CD4 CCR6
20	perinatal necrotizing enterocolitis	30.5	TNF IL6 IL17A CD4 CCR6
21	arteries, anomalies of	30.5	TNF MIR199A1 IL6 CCR6
22	diarrhea	30.5	TNF IL6 IFNB1 EGFR
23	intestinal perforation	30.5	TNF IL6 CD8A CD4 CCR6
24	sialadenitis	30.5	TNF CD4 CCR6
25	herpes simplex	30.5	RSAD2 PML IFNB1 GYPC CD8A
26	exanthem	30.5	TNF IL6 IL17A EGFR CD8A CD4
27	anemia, autoimmune hemolytic	30.5	IL6 CD8A CD4 CCR6
28	thrombocytopenia due to platelet alloimmunization	30.4	CD8A CD4 CCR6
29	thrombocytopenic purpura, autoimmune	30.4	CD8A CD4 CCR6
30	vascular disease	30.4	TNF MIR199A1 MAPK1 IL6 CCR6
31	combined immunodeficiency	30.4	TNF IL6 IL17A CD8A CD4 CCR6
32	pharyngitis	30.4	TNF IL6 CD8A CD4 CCR6
33	duodenitis	30.4	TNF CD8A CD4
34	ileus	30.4	TNF IL6 IL17A
35	legionnaire disease	30.4	TNF IL6 CD4
36	hemorrhagic cystitis	30.4	TNF IL6 CD8A CD4
37	demyelinating polyneuropathy	30.4	TNF IL6 CD8A CD4
38	viral infectious disease	30.4	TNF MIR199A1 IL6 IL17A IFNB1 CD4
39	adult-onset still's disease	30.4	TNF IL6 CCR6
40	cryptosporidiosis	30.3	TNF CD8A CD4
41	portal hypertension	30.3	TNF MIR199A1 CCR6
42	aortic aneurysm, familial abdominal, 1	30.3	TNF MIR199A1 IL6 CCR6
43	pneumonia	30.3	TNF IL6 IL17A CD8A
44	syphilis	30.3	TNF IL17A CD8A CD4 CCR6
45	henoch-schoenlein purpura	30.3	TNF IL6 CD4 CCR6
46	inflammatory bowel disease 1	30.3	TNF IL6 IL17A CCR6
47	histiocytosis	30.3	TNF IL17A CCR6
48	chlamydia	30.3	TNF IL6 IL17A
49	dermatitis	30.3	TNF IL6 IL17A CCR6
50	juvenile rheumatoid arthritis	30.3	TNF IL6 CD4 CCR6

Comorbidity relations with Human Cytomegalovirus Infection via Phenotypic Disease Network (PDN):

Acute Cystitis	Deficiency Anemia
Heart Disease

Graphical network of the top 20 diseases related to Human Cytomegalovirus Infection:

Sources

Symptoms & Phenotypes for Human Cytomegalovirus Infection

UMLS symptoms related to Human Cytomegalovirus Infection:

fever; pruritus

MGI Mouse Phenotypes related to Human Cytomegalovirus Infection:

⁴⁵

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	nervous system	MP:0003631	9.93	B3GAT1 CCR6 CD4 CD8A EGFR HLA-E
2	no phenotypic analysis	MP:0003012	9.91	CD4 EGFR HLA-E IFNB1 IL17A KLRD1
3	immune system	MP:0005387	9.83	CCR6 CD4 CD8A EGFR HLA-E IFNB1
4	hematopoietic system	MP:0005397	9.5	CCR6 CD4 CD8A EGFR GYPC HLA-E

Sources

Drugs & Therapeutics for Human Cytomegalovirus Infection

Drugs for Human Cytomegalovirus Infection (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 158)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Prednisone

Approved, Vet_approved

Phase 4

53-03-2

5865

Miconazole

Approved, Investigational, Vet_approved

Phase 4

22916-47-8

4189

Clotrimazole

Approved, Vet_approved

Phase 4

23593-75-1

2812

Benzocaine

Approved, Investigational

Phase 4

1994-09-7, 94-09-7

2337

Basiliximab

Approved, Investigational

Phase 4

179045-86-4

Hydrocortisone

Approved, Vet_approved

Phase 4

50-23-7

3640 5754

Tannic acid

Approved

Phase 4

1401-55-4

16129878 16129778

Hydrocortisone succinate

Approved

Phase 4

2203-97-6

3643

Hydrocortisone acetate

Approved, Vet_approved

Phase 4

50-03-3

Metamizole

Approved, Investigational, Withdrawn

Phase 4

50567-35-6

3111 522325

Magnesium sulfate

Approved, Investigational, Vet_approved

Phase 4

7487-88-9

Formaldehyde

Approved, Vet_approved

Phase 4

50-00-0

712

Letermovir

Approved, Investigational

Phase 4

917389-32-3

9916099 45138674

Mycophenolic acid

Approved, Investigational

Phase 4

24280-93-1

446541

Sirolimus

Approved, Investigational

Phase 4

53123-88-9

5284616 6436030

Tacrolimus

Approved, Investigational

Phase 4

104987-11-3

6473866 445643

Everolimus

Approved

Phase 4

159351-69-6

70789204 6442177

Triamcinolone

Approved, Vet_approved

Phase 4

124-94-7

31307

Valaciclovir

Approved, Investigational

Phase 4

124832-27-5, 124832-26-4

60773 135398742

Ganciclovir

Approved, Investigational

Phase 4

82410-32-0

3454

Ophthalmic Solutions

Phase 4

Antifungal Agents

Phase 4

Hormones

Phase 4

Hormone Antagonists

Phase 4

Calcineurin Inhibitors

Phase 4

Hydrocortisone 17-butyrate 21-propionate

Phase 4

Gastrointestinal Agents

Phase 4

Antineoplastic Agents, Hormonal

Phase 4

Antiemetics

Phase 4

Protective Agents

Phase 4

Neuroprotective Agents

Phase 4

Calcium, Dietary

Phase 4

Anesthetics

Phase 4

Anticonvulsants

Phase 4

Tocolytic Agents

Phase 4

Analgesics

Phase 4

calcium channel blockers

Phase 4

Anti-Arrhythmia Agents

Phase 4

Reverse Transcriptase Inhibitors

Phase 4

Poly(ADP-ribose) Polymerase Inhibitors

Phase 4

Immunologic Factors

Phase 4

Immunosuppressive Agents

Phase 4

Antibiotics, Antitubercular

Phase 4

Anti-Bacterial Agents

Phase 4

Antitubercular Agents

Phase 4

Thymoglobulin

Phase 4

Antilymphocyte Serum

Phase 4

Triamcinolone hexacetonide

Phase 4

Triamcinolone diacetate

Phase 4

Triamcinolone Acetonide

Phase 4

6436

Interventional clinical trials:

(show top 50) (show all 300)

#	Name	Status	NCT ID	Phase	Drugs
1	Conversion to Sirolimus: Effects in Cytomegalovirus Infection Recurrence in Kidney Transplant Recipients (StopCMV: S=Sirolimus CMV= Cytomegalovirus)	Unknown status	NCT02671318	Phase 4	Drug conversion to sirolimus;Maintenance of the current regimen
2	Intra-cameral Penetration and Efficacy of Ganciclovir Following Topical Administration of 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis	Unknown status	NCT02943057	Phase 4	2% guttae ganciclovir
3	An Exploratory Evaluation of Early Use of Everolimus (EVE) on Tacrolimus (TAC)-Based Immunosuppressive Regiment vs. Mycophenolate Sodium (MPS) on Cytomegalovirus (CMV) Infection in Renal Transplant Recipients.	Unknown status	NCT01927588	Phase 4	Everolimus+Tacrolimus+Prednisone;Mycophenolate+Tacrolimus+Prednisone
4	The Influence of Chronic Cytomegalovirus Infection on Influenza Vaccine Responses	Completed	NCT02134184	Phase 4
5	Phase IV.II Pilot Study of Treatment of Cytomegalovirus Infection With a Brief Induction With Ganciclovir i.v. Followed by Valganciclovir Oral in Solid Organ Transplant Patients.	Completed	NCT00730769	Phase 4	Single arm (ganciclovir and valganciclovir)
6	Determining a Viral Load Threshold for Pre-emptive Therapy for Cytomegalovirus Infection in Transplant Patients Using Real Time Polymerase Chain Reaction (PCR) Monitoring	Completed	NCT00947141	Phase 4	ganciclovir (start when CMV PCR >200copies / ml x2);Stop treatment when 2 levels CMV PCR <3,000 copies / ml
7	Prophylaxis Versus Preemptive Therapy for the Prevention of CMV in High-Risk R-D+ Liver Transplant Recipients	Completed	NCT01552369	Phase 4	Valganciclovir
8	Open, Randomised Study Comparing Preemptive Therapy With Intravenous Ganciclovir With and Without Additional Oral Ganciclovir for CMV Prophylaxis in Immunosuppressed Renal Transplant Patients Receiving Monitoring of CMV Viral Load	Completed	NCT00373165	Phase 4	Ganciclovir
9	Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate	Completed	NCT01354301	Phase 4	Thymoglobulin;Everolimus;Basiliximabe;mycophenolate sodium;Tacrolimus
10	A Multicenter, Two Arms, Randomized, Open Label Clinical Phase IV Study Investigating the Proportion of CMV Seropositive Kidney Transplant Recipients Who Will Develop a CMV Infection Within the First 6 Months Post-transplantation When Treated With an Immunosuppressive Regimen Including Everolimus (Certican®) and Reduced Dose of Cyclosporine A (Neoral®) Versus an Immunosuppressive Regimen With Mycophenolic Acid (Myfortic®) and Standard Dose of Cyclosporine A (Neoral®).	Completed	NCT02328963	Phase 4	Everolimus;mycophenolic acid
11	Everolimus in Association With Very Low-dose Tacrolimus Versus Enteric-coated Mycophenolate Sodium With Low-dose Tacrolimus in de Novo Renal Transplant Recipients - A Prospective Single Center Study	Completed	NCT02084446	Phase 4	Everolimus;Very Low Tacrolimus;Low Tacrolimus;Steroids;Thymoglobulin;Sodium Mycophenolate
12	Sirolimus Associated With Tacrolimus at Low Doses in Elderly Kidney Transplant Patients: A Prospective Randomized Controlled Trial	Completed	NCT02683291	Phase 4	sirolimus;tacrolimus;mycophenolate;Prednisone;Basiliximab;Thymoglobulin
13	Tolerability of up to 200 Days of Valganciclovir Oral Solution or Tablets in Pediatric Kidney Transplant Recipients	Completed	NCT01376804	Phase 4	valganciclovir [Valcyte]
14	A Randomized, Open-label Study of the Effect of Oral Valcyte Versus Intravenous Ganciclovir on CMV Viremia in Solid Organ Transplant Patients	Completed	NCT00431353	Phase 4	Ganciclovir;valganciclovir [Valcyte]
15	Safety and Efficacy of Intravenous Magnesium Sulfate in Modulating Changes in Symptoms and Divalent Cation Levels Associated With Foscavir Therapy: A Phase IV Randomized, Double-Blind, Placebo-Controlled, Cross-Over, Pilot Study	Completed	NCT00002146	Phase 4	Magnesium sulfate;Foscarnet sodium
16	Valganciclovir to Reduce T Cell Activation in HIV Infection	Completed	NCT00264290	Phase 4	Valganciclovir;Placebo
17	A Multicenter Prospective Cohort Study to Investigate if Ganciclovir Significantly Affects Spermatogenesis in Adult Male Renal Transplant Recipients Receiving up to 200 Days Valganciclovir Vs. Concurrent Untreated Matched Controls	Completed	NCT01663740	Phase 4	Valganciclovir
18	Cytogam Administration in Abdominal Organ Transplant Recipients at High Risk for CMV Infection	Completed	NCT01509404	Phase 4	Valganciclovir
19	A Prospective Randomized Study for Predicting Human Cytomegalovirus (hCMV) Infection According to Baseline hCMV-specific T-cell Response in Kidney Transplant Patients (RESPECT)	Completed	NCT02550639	Phase 4
20	Influence of Persistent CMV-infection on Immune Senescence Evaluated With a Prospective Vaccination Trial Against Tick-borne Encephalitis Virus in Healthy Elderly Individuals (CYTEL-Study)	Completed	NCT00461695	Phase 4
21	In Utero Treatment of Cytomegalovirus congénitale Infection With Valacyclovir : Prospective Multicenter Nonrandomized Trial	Completed	NCT01651585	Phase 4	Valacyclovir arrow
22	Phase IV Clinical Trial, Open, Randomized, Controlled and Multicentric, With Two Parallel Groups, to Assess the Efficacy of a Preventive Strategy Against Cytomegalovirus Infection in Heart Transplant Patients, Based on the Specific Basal T Cell Response Against Cytomegalovirus: ELISPOT-TC	Recruiting	NCT04278547	Phase 4
23	Cytomegalovirus Specific Cytotoxic T Lymphocyte for the Treatment of Cytomegalovirus Infection After Allogeneic Hematopoietic Stem Cell Transplantation	Recruiting	NCT03004261	Phase 4	Foscarnet;Ganciclovir
24	Evaluation of the Tolerability and Clinical Effectiveness of Letermovir in Heart Transplantation	Active, not recruiting	NCT04904614	Phase 4	Letermovir
25	Effect of the Introduction of mTor Inhibitors in the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response to Control Viral Replication in Kidney Transplant Patients	Not yet recruiting	NCT04936971	Phase 4	Switch from Mycophenolate Mofetil to Everolimus manteinance treatment in Active Comparator Arm
26	In UTERO Treatment of Cytomegalovirus Congenital Infection With Valacyclovir: Prospective Multicenter Randomized Trial Versus Placebo	Terminated	NCT01037712	Phase 4	Valacyclovir (ZELITREX);Placebo
27	Ganciclovir Pharmacokinetics in Patients Undergoing Continuous Renal Replacement Therapy	Terminated	NCT00264368	Phase 4	intravenous (IV) ganciclovir
28	The Impact of Co-infections on Inflammation in Patients Commencing Second-line Antiretroviral Therapy. A Sub-study of D²EFT (Dolutegravir and Darunavir Evaluation in Adults Failing Therapy)	Withdrawn	NCT04183738	Phase 4	NRTIs;Darunavir;Ritonavir;Dolutegravir
29	Efficacy and Safety of Anti-cytomegalovirus Prophylaxis Versus Pre-emptive Approaches With Valganciclovir in Heart Transplant Recipients Treated With Everolimus or Mycophenolate. A Randomized Open-label Study for Prevention of Cardiaca Allograft Vasculopathy	Unknown status	NCT00966836	Phase 3	Pre-emptive strategy with valganciclovir plus everolimus;Prophylaxis with valganciclovir plus mycophenolate;Prophylaxis with valganciclovir plus everolimus;Pre-emptive mycophenolate
30	Myocardial Screening in Fetuses With Congenital Cytomegalovirus (CMV) Infection	Unknown status	NCT02787382	Phase 3
31	A Randomized Trial to Prevent Congenital Cytomegalovirus (CMV)	Completed	NCT01376778	Phase 3	CMV hyperimmune globulin
32	Phase III Randomized, Controlled Study of Ganciclovir for Symptomatic Congenital Cytomegalovirus Infection	Completed	NCT00004278	Phase 3	ganciclovir
33	A Phase III Multicenter Study Of Valganciclovir For The Prevention Of Late Cytomegalovirus Infection After Allogeneic Hematopoietic Stem Cell Transplantation	Completed	NCT00016068	Phase 3	ganciclovir;valganciclovir
34	Participation of Cytomegalovirus Infection or an Autoimmune Process in T Lymphocyte Activation of HIV-1 Infected Patients With Undetectable Viral Load on Antiretroviral Therapy.	Completed	NCT04067869	Phase 3
35	A Phase III, Randomized, Placebo-Controlled Blinded Investigation of Six Weeks vs. Six Months of Oral Valganciclovir Therapy in Infants With Symptomatic Congenital Cytomegalovirus Infection (CASG 112)	Completed	NCT00466817	Phase 3	Valganciclovir
36	A Phase III Multicenter Study of Valganciclovir for the Prevention of Late Cytomegalovirus Infection After Allogenic Hematopoietic Stem Cell Transplantation.	Completed	NCT00275665	Phase 3	Valganciclovir
37	A Phase 3 Randomized, Double-blind, Placebo-controlled Clinical Trial to Evaluate the Safety and Efficacy of Letermovir (LET) Prophylaxis When Extended From 100 Days to 200 Days Post-transplant in Cytomegalovirus (CMV) Seropositive Recipients (R+) of an Allogenic Hematopoietic Stem Cell Transplant (HSCT)	Completed	NCT03930615	Phase 3	Letermovir;Placebo
38	A Phase III Randomised Study to Investigate the Use of Adoptive Cellular Therapy (ACT) in Combination With Conventional Antiviral Drug Therapy for the Treatment of CMV Reactivation Episodes in Patients Following Allogeneic Haematopoietic Stem Cell Transplant	Completed	NCT01077908	Phase 3	Best available antiviral drug therapy
39	Prevention of Human Cytomegalovirus (HCMV) Mother-to-fetus Transmission by Administration of Virus-specific Hyperimmune Globulin to Pregnant Women With Primary HCMV Infection	Completed	NCT00881517	Phase 2, Phase 3	HCMV-specific hyperimmune globulin (Cytotect®);Isotonic solution of sodium chloride (placebo)
40	The Leiden CONCERT Study 2.0 Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Non-Randomized Trial With Historical Control Group	Completed	NCT02005822	Phase 3	Valganciclovir
41	Valacyclovir to Prevent Vertical Transmission of Cytomegalovirus After Maternal Primary Infection During Pregnancy	Completed	NCT02351102	Phase 2, Phase 3	Valacyclovir;Placebo
42	A Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Prophylactic Use of Maribavir for the Prevention of Cytomegalovirus Disease in Recipients of Allogeneic Stem Cell Transplants.	Completed	NCT00411645	Phase 3	maribavir
43	A Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study of the Efficacy and Safety of up to 100 Days of Valganciclovir Versus up to 200 Days of Valganciclovir for Prevention of Cytomegalovirus (CMV) Disease in High-Risk Kidney Allograft Recipients	Completed	NCT00294515	Phase 3	Valganciclovir
44	A Phase III, Randomized, Double-Blind Comparison of Oral Valganciclovir and Placebo for Prevention of CMV After Lung Transplantation	Completed	NCT00227370	Phase 3	valganciclovir
45	A Phase III Study to Evaluate the Safety and Efficacy of Ganciclovir (Dihydroxypropoxymethyl Guanine [DHPG]) Treatment of Symptomatic Central Nervous System (CNS) Congenital Cytomegalovirus (CMV) Infections.	Completed	NCT00001100	Phase 3	ganciclovir
46	A Randomized Trial Comparing Valcyte CMV Prophylaxis Versus Pre-emptive Therapy After Renal Transplantation Using Proteomics for Monitoring of Graft Alteration	Completed	NCT00372229	Phase 3	Valganciclovir CMV Prophylaxis;Valganciclovir (Pre-emptive CMV Therapy);Ganciclovir
47	Safety and Pharmacokinetics of Valganciclovir Syrup Formulation in Pediatric Solid Organ Transplant Recipients	Completed	NCT00090766	Phase 2, Phase 3	valganciclovir [Valcyte]
48	Transfusion-Transmitted Cytomegalovirus Prevention in Neonates	Completed	NCT00000584	Phase 3	immunoglobulins
49	A Randomized, Double-blind Study To Assess The Efficacy And Safety Of Prophylactic Use Of Maribavir Versus Oral Ganciclovir For The Prevention Of Cytomegalovirus Disease In Recipients Of Orthotopic Liver Transplants	Completed	NCT00497796	Phase 3	maribavir;ganciclovir
50	A Phase III, Prospective, Randomized, Double-Blind Trial of Valganciclovir Pre-Emptive Therapy for Cytomegalovirus (CMV) Viremia as Detected by Plasma CMV DNA PCR Assay	Completed	NCT00006145	Phase 3	Valganciclovir

Search NIH Clinical Center for Human Cytomegalovirus Infection

Inferred drug relations via UMLS ⁷¹ / NDF-RT ⁵⁰ :

Cidofovir

Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor [EPC]

Cytomegalovirus Pyrophosphate Analog DNA Polymerase Inhibitor [EPC]

Foscarnet

Foscarnet Sodium Hexahydrate

Ganciclovir

Ganciclovir Sodium

Immunoglobulins, Intravenous

valganciclovir

Valganciclovir hydrochloride

Sources

Genetic Tests for Human Cytomegalovirus Infection

Genetic tests related to Human Cytomegalovirus Infection:

#	Genetic test	Affiliating Genes
1	Cytomegalovirus Infection ²⁸

Sources

Anatomical Context for Human Cytomegalovirus Infection

Organs/tissues related to Human Cytomegalovirus Infection:

MalaCards : T Cells, Bone Marrow, Kidney, Liver, Heart, Lung, Bone

Sources

Publications for Human Cytomegalovirus Infection

Articles related to Human Cytomegalovirus Infection:

(show top 50) (show all 10143)

#	Title	Authors	PMID	Year
1	Promyelocytic Leukemia Protein Potently Restricts Human Cytomegalovirus Infection in Endothelial Cells. ⁶² ⁴¹	Seitz S...Scherer M	36233232	2022
2	Association between active cytomegalovirus infection and lung fibroproliferation in adult patients with acute respiratory distress syndrome: a retrospective study. ⁶² ⁴¹	Zhang Z...Li Y	36241980	2022
3	CXCL8, CCL2, and CMV Seropositivity as New Prognostic Factors for a Severe COVID-19 Course. ⁴¹	Pius-Sadowska E...Machalinski B	36232655	2022
4	Neurological evaluation of microcephalic children with Zika syndrome and congenital cytomegalovirus infection. ⁶²	Faccini LS...da Silva Inacio de Bone S	36164338	2022
5	MORC3 restricts human cytomegalovirus infection by suppressing the major immediate-early promoter activity. ⁶²	Ma XH...Yang B	35879101	2022
6	Audiovestibular Consequences of Congenital Cytomegalovirus Infection: Greater Vulnerability of the Vestibular Part of the Inner Ear. ⁶²	Chebib E...Wiener Vacher SR	35687026	2022
7	Impact of cytomegalovirus infection prior to hematopoietic stem cell transplantation in children with inborn errors of immunity. ⁶²	Del Rosal T...Mendez-Echevarria A	36102997	2022
8	Efficacy of pp65-specific TCR-T cell therapy in treating cytomegalovirus infection after hematopoietic stem cell transplantation. ⁶²	Liu G...Lin X	36054234	2022
9	Absolute Lymphocyte Count as a Marker for Cytomegalovirus Infection After Heart Transplantation. ⁶²	Schoeberl AK...Goekler J	36228318	2022
10	[Congenital cytomegalovirus infection, is more prevalent in our country in newborns exposed to HIV?] ⁶²	Bustamante-Amador J...Grupo de Trabajo sobre Infeccion Perinatal-Neonatologia-Ginecologia (GINPER)	35841598	2022
11	RNA-Seq of amniotic fluid cell-free RNA: a discovery phase study of the pathophysiology of congenital cytomegalovirus infection. ⁶²	Hui L...Hannan NJ	35609640	2022
12	Gastric outlet obstruction due to cytomegalovirus infection in an immunocompetent child. ⁶²	Semwal P...Bhat NK	36201095	2022
13	Cytomegalovirus infection disrupts the influence of short-chain fatty acid producers on Treg/Th17 balance. ⁶²	Chin N...Hartigan-O'Connor DJ	36210471	2022
14	Risk factors for cytomegalovirus infection and disease after kidney transplantation: A meta-analysis. ⁶²	Tang Y...Qiu T	35901951	2022
15	Maternal high-dose valacyclovir and its correlation with newborn blood viral load and outcome in congenital cytomegalovirus infection. ⁶²	Gonce A...Figueras F	33143511	2022
16	Congenital cytomegalovirus infection diagnostics and management. ⁶²	Pinninti S...Boppana S	35984001	2022
17	Intra-host diversity of drug-resistant cytomegalovirus: A case report of cytomegalovirus infection after allogeneic hematopoietic cell transplantation. ⁶²	Jung JY...Oh EJ	35810104	2022
18	Describing the Impact of Maternal Hyperimmune Globulin and Valacyclovir on the Outcomes of Cytomegalovirus Infection in Pregnancy: A Systematic Review. ⁶²	Fitzpatrick A...Ritchie B	35438780	2022
19	Severe gastritis in a patient treated with immunotherapy: immune-mediated or reactivation of cytomegalovirus? ⁶²	Vallejo Rivera SR...Diaz Concepcion J	36205315	2022
20	The immune factors driving DNA methylation variation in human blood. ⁶²	Bergstedt J...Milieu Interieur Consortium	36202838	2022
21	[Cytomegalovirus screening during pregnancy : an ongoing debate still in 2022]. ⁶²	Pecheux O...Martinez De Tejada B	36259702	2022
22	Inferring differential subcellular localisation in comparative spatial proteomics using BANDLE. ⁶²	Crook OM...Lilley KS	36216816	2022
23	Impact of induction therapy on cytomegalovirus infection and post-transplant outcomes in pediatric heart transplant recipients receiving routine antiviral prophylaxis. ⁶²	Zang S...Das BB	36259556	2022
24	Acute cytomegalovirus infection modulates the intestinal microbiota and targets intestinal epithelial cells. ⁶²	Le-Trilling VTK...Westendorf AM	36250419	2022
25	The epidemiology and disease burden of congenital TORCH infections among hospitalized children in China: A national cross-sectional study. ⁶²	Zhang L...Xie Z	36240247	2022
26	Retinopathy of Prematurity and Possible Relation Between Postnatal Cytomegalovirus Infection. ⁶²	Josa M...Moliner E	35441956	2022
27	[Analysis of risk factors and prognosis of cytomegalovirus infection post umbilical cord blood stem cell transplantation in children with primary immunodeficiency diseases]. ⁶²	Wei ZL...Zhai XW	36207848	2022
28	Good Long-Term Outcome Following Liver Transplant in a Patient With Common Variable Immunodeficiency Syndrome Despite Multiple Infections and Recurrent Nodular Regenerative Hyperplasia. ⁶²	Bonatti HJR...Pruett TL	36259616	2022
29	Comparative clinical manifestations and immune effects of cytomegalovirus infections following distinct types of immunosuppression. ⁶²	Ong DSY...Cremer OL	35709902	2022
30	The association between congenital cytomegalovirus infection and cerebral palsy: A systematic review and meta-analysis. ⁶²	Ong LT...Fan SWD	36250689	2022
31	Postchemotherapy immune status in infants with acute lymphoblastic leukemia: A report from the JPLSG MLL-10 trial. ⁶²	Arakawa Y...Tomizawa D	35796397	2022
32	[Intestinal pseudo-obstruction: An infrequent manifestation of cytomegalovirus infection]. ⁶²	Eguzkiza-Ezponda L...Branas F	36253305	2022
33	Brainstem auditory pathway maturation in term neonates with congenital cytomegalovirus infection: a cohort study. ⁶²	Kassis I...Meir M	36207473	2022
34	Integration of UPLC-QE-MS/MS and network pharmacology to investigate the active components and action mechanisms of tea cake extract for treating cough. ⁶²	Lin C...Li L	35781817	2022
35	A systematic review and meta-analysis of the prevalence of human cytomegalovirus shedding in seropositive pregnant women. ⁶²	Sapuan S...Jones CE	36196755	2022
36	Current state of clinical trials regarding lung transplant rejection. ⁶²	Rifi R...Salameh P	35842078	2022
37	Mouse Models for Cytomegalovirus Infections in Newborns and Adults. ⁶²	Brizic I...Jonjic S	36083111	2022
38	Maribavir for Refractory Cytomegalovirus Infections With or Without Resistance Post-Transplant: Results From a Phase 3 Randomized Clinical Trial. ⁶²	Avery RK...SOLSTICE Trial Investigators	34864943	2022
39	Exposure to heat stress causes downregulation of immune response genes and weakens the disease resistance of Micropterus salmoides. ⁶²	Yang C...Ye X	35839613	2022
40	Real-world efficacy of letermovir prophylaxis for cytomegalovirus infection after allogeneic hematopoietic stem cell transplantation: A single-center retrospective analysis. ⁶²	Yoshimura H...Nomura S	35725529	2022
41	Cancer risk associated with cytomegalovirus infection among solid organ transplant recipients in the United States. ⁶²	Geris JM...Engels EA	36126024	2022
42	Cytomegalovirus infection in patients with malignant lymphomas who have not received hematopoietic stem cell transplantation. ⁶²	Sato K...Torimoto Y	36050665	2022
43	Role of PARP-1 in Human Cytomegalovirus Infection and Functional Partners Encoded by This Virus. ⁶²	Zhang W...Chen Q	36146855	2022
44	Everolimus Use in Lung Transplant Recipients. ⁶²	Turkkan S...Yekeler E	36192210	2022
45	Effect of sorafenib maintenance on Epstein-Barr virus and cytomegalovirus infections in patients with FLT3-ITD AML undergoing allogeneic hematopoietic stem cell transplantation: a secondary analysis of a randomized clinical trial. ⁶²	Xu X...Xuan L	36050712	2022
46	Romiplostim use in pregnant women with immune thrombocytopenia. ⁶²	Bussel JB...Saad H	36156812	2022
47	Prenatal infection and schizophrenia: A decade of further progress. ⁶²	Cheslack-Postava K...Brown AS	34016508	2022
48	Risk factors and incidence of cytomegalovirus viremia and disease in pediatric patients with allogeneic hematopoietic stem cell transplantation: An 8-year single-center experience in Latin America. ⁶²	Aristizabal AM...Medina D	35647735	2022
49	Maribavir Pharmacokinetics and Safety in Participants With Moderate Hepatic Impairment: A Phase 1, Open-Label, Single-Dose, Parallel Group Study. ⁶²	Song I...Ilic K	36089648	2022
50	Universal first-trimester cytomegalovirus screening and valaciclovir prophylaxis in pregnant persons: a cost-effectiveness analysis. ⁶²	Fisher SA...Premkumar A	35714861	2022

Sources

Genes for Human Cytomegalovirus Infection

Genes related to Human Cytomegalovirus Infection (0 elite genes):

(show all 27)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	PML	PML Nuclear Body Scaffold	Protein Coding	12.18	DISEASES inferred ¹⁴ GeneCards inferred via : Publications (show sections)
2	STX5	Syntaxin 5	Protein Coding	7.72	GeneCards inferred via : Functions (show sections)
3	MIR199A1	MicroRNA 199a-1	RNA Gene	6.6	DISEASES inferred ¹⁴ ¹⁴
4	KLRC2	Killer Cell Lectin Like Receptor C2	Protein Coding	6.36	DISEASES inferred ¹⁴
5	CCR6	C-C Motif Chemokine Receptor 6	Protein Coding	5.81	DISEASES inferred ¹⁴ ¹⁴
6	KLRD1	Killer Cell Lectin Like Receptor D1	Protein Coding	5.56	DISEASES inferred ¹⁴
7	LILRB1	Leukocyte Immunoglobulin Like Receptor B1	Protein Coding	5.54	DISEASES inferred ¹⁴
8	HLA-E	Major Histocompatibility Complex, Class I, E	Protein Coding	5.41	DISEASES inferred ¹⁴
9	IL17A	Interleukin 17A	Protein Coding	5.41	DISEASES inferred ¹⁴
10	CD8A	CD8a Molecule	Protein Coding	5.34	DISEASES inferred ¹⁴
11	RSAD2	Radical S-Adenosyl Methionine Domain Containing 2	Protein Coding	5.32	DISEASES inferred ¹⁴
12	KLRC1	Killer Cell Lectin Like Receptor C1	Protein Coding	5.32	DISEASES inferred ¹⁴
13	TNF	Tumor Necrosis Factor	Protein Coding	5.3	DISEASES inferred ¹⁴
14	GYPC	Glycophorin C (Gerbich Blood Group)	Protein Coding	5.24	DISEASES inferred ¹⁴
15	CD4	CD4 Molecule	Protein Coding	5.15	DISEASES inferred ¹⁴
16	B3GAT1	Beta-1,3-Glucuronyltransferase 1	Protein Coding	5.14	DISEASES inferred ¹⁴
17	IL6	Interleukin 6	Protein Coding	5.06	DISEASES inferred ¹⁴
18	MAPK1	Mitogen-Activated Protein Kinase 1	Protein Coding	4.98	DISEASES inferred ¹⁴
19	EGFR	Epidermal Growth Factor Receptor	Protein Coding	4.93	DISEASES inferred ¹⁴
20	IFNB1	Interferon Beta 1	Protein Coding	4.9	DISEASES inferred ¹⁴
21	KIR3DL1	Killer Cell Immunoglobulin Like Receptor, Three Ig Domains And Long Cytoplasmic Tail 1	Protein Coding	4.89	DISEASES inferred ¹⁴
22	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	4.84	DISEASES inferred ¹⁴
23	PTGS2	Prostaglandin-Endoperoxide Synthase 2	Protein Coding	4.83	DISEASES inferred ¹⁴
24	KIR2DL1	Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 1	Protein Coding	4.81	DISEASES inferred ¹⁴
25	RELA	RELA Proto-Oncogene, NF-KB Subunit	Protein Coding	4.79	DISEASES inferred ¹⁴
26	IL10	Interleukin 10	Protein Coding	4.76	DISEASES inferred ¹⁴
27	KLRK1	Killer Cell Lectin Like Receptor K1	Protein Coding	4.76	DISEASES inferred ¹⁴

Sources

Variations for Human Cytomegalovirus Infection

Sources

Expression for Human Cytomegalovirus Infection

Search GEO for disease gene expression data for Human Cytomegalovirus Infection.

Sources

Pathways for Human Cytomegalovirus Infection

Pathways related to Human Cytomegalovirus Infection according to GeneCards Suite gene sharing:

(show all 37)

#	Super pathways	Score	Top Affiliating Genes
1	Innate Immune System ⁶⁶ Show member pathways Immune System ⁶⁶ Neutrophil degranulation ⁶⁶	13.68	CCR6 CD4 CD8A HLA-E IFNB1 IL17A
2	MIF Mediated Glucocorticoid Regulation ⁶⁴ Show member pathways all-trans-Retinoic Acid Signaling in Brain ⁶⁴ Endothelin-1 Signaling Pathway ⁶⁴ Glucocorticoid Receptor Signaling ⁶⁴ IL-6 Pathway ⁶⁴ MIF Regulation of Innate Immune Cells ⁶⁴ NFAT Signaling and Lymphocyte Interactions ⁶⁴ Overview of proinflammatory and profibrotic mediators ⁷⁴ PEDF Induced Signaling ⁶⁴ PGC1Alpha Pathway ⁶⁴ RAR-Gamma-RXR-Alpha Degradation ⁶⁴ STAT3 Pathway ⁶⁴	13.58	TNF MAPK1 IL6 IL17A IFNB1 EGFR
3	PAK Pathway ⁶⁴ Show member pathways Antioxidant Action of Vitamin-C ⁶⁴ Epithelial Adherens Junctions ⁶⁴	13.24	CCR6 CD4 EGFR IL17A IL6 MAPK1
4	Cytokine Signaling in Immune system ⁶⁶ Show member pathways Signaling by Interleukins ⁶⁶	13.23	TNF RSAD2 PML MAPK1 IL6 IL17A
5	4-1BB Pathway ⁶⁴ Show member pathways CD27 Pathway ⁶⁴ CD40 Signaling ⁶⁴ CMV and MAPK Pathways ⁶⁴ NF-KappaB Activation by EBV ⁶⁴ NF-kappaB Activation by Viruses ⁶⁴ PKR Pathway ⁶⁴ SUMO Pathway ⁶⁴ TNFR2 Pathway ⁶⁴	12.61	TNF PML MAPK1 EGFR CD4
6	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ⁶¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ⁶¹ Immune response IL-10 signaling pathway ²² RAC1/PAK1/p38/MMP2 pathway ⁷⁴	12.53	TNF MAPK1 IL6 IL17A EGFR CD4
7	NF-kappaB Signaling ³	12.51	CD8A IL17A LILRB1 RSAD2 TNF
8	Toll-Like receptor Signaling Pathways ⁶⁵ Show member pathways Inflammasome Activation Pathways ⁶⁵ Nanomaterial-induced inflammasome activation ⁷⁴ NOD-like Receptor Signaling Pathways ⁶⁵ TLR4 signaling and tolerance ⁷⁴ Toll-Like Receptors Pathway ⁶⁴	12.46	TNF MAPK1 IL6 IFNB1
9	IL-17 Family Signaling Pathways ⁶⁵ Show member pathways "Mucin expression in CF via IL-6, IL-17 signaling pathways" ²² IL17 signaling pathway ⁶⁷ IL-17 signaling pathway ⁷⁴	12.23	TNF MAPK1 IL6 IL17A
10	Colorectal Cancer Metastasis ⁶⁴	12.14	TNF MAPK1 IL6 EGFR
11	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.11	TNF RSAD2 PML MAPK1 IL6 IL17A
12	Immune response CD16 signaling in NK cells ²² Show member pathways Immune response Role of DAP12 receptors in NK cells ²²	12.07	HLA-E KLRC1 KLRC2 KLRD1 MAPK1 TNF
13	Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell ⁶⁶	12	CD8A HLA-E KLRC1 KLRD1 LILRB1
14	T-cell activation SARS-CoV-2 ⁷⁴ Show member pathways T-cell antigen receptor (TCR) pathway during Staphylococcus aureus infection ⁷⁴	11.98	TNF MAPK1 IL17A IFNB1 CD8A CD4
15	Spinal cord injury ⁷⁴	11.95	TNF MAPK1 IL6 EGFR
16	IL27-mediated signaling events ⁶¹ Show member pathways IL12 signaling pathway ⁶⁷ Th1 Differentiation ⁶⁵	11.87	TNF IL6 IL17A CD4
17	Th17 Differentiation ⁶⁵ Show member pathways IL-21 Signaling and its Primary Biological Effects in Different Immune Cell Types ⁶⁵	11.81	IL6 IL17A CD4
18	Network map of SARS-CoV-2 signaling pathway ⁷⁴ Show member pathways Pathogenesis of SARS-CoV-2 mediated by nsp9-nsp10 complex ⁷⁴	11.74	IL6 IFNB1 CD8A CD4
19	Acute viral myocarditis ⁷⁴	11.71	CD4 IL6 MAPK1
20	Burn wound healing ⁷⁴	11.71	IFNB1 IL6 TNF
21	DAP12 interactions ⁶⁶ Show member pathways DAP12 signaling ⁶⁶	11.7	HLA-E KLRC2 KLRD1
22	Hematopoietic Stem Cells and Lineage-specific Markers ⁶⁵	11.7	TNF KLRC2 KLRC1 IL6 CD8A CD4
23	Th17 cell differentiation pathway ⁷⁴	11.68	CD4 IL17A IL6 MAPK1
24	Dendritic Cells Developmental Lineage Pathway ⁶⁵	11.67	TNF IL6 IFNB1 CD8A CD4
25	Photodynamic therapy-induced NF-kB survival signaling ⁷⁴ Show member pathways Immune response MIF-mediated glucocorticoid regulation ²²	11.62	TNF MAPK1 IL6
26	miRNAs involvement in the immune response in sepsis ⁷⁴	11.61	TNF MIR199A1 IL6
27	NF-kB (NFkB) Pathway ⁶⁷	11.55	TNF MAPK1 HLA-E CD4
28	"Non-genomic actions of 1,25 dihydroxyvitamin D3" ⁷⁴	11.51	TNF MAPK1 IL6
29	Fibrin complement receptor 3 signaling pathway ⁷⁴	11.41	TNF IL6 IFNB1
30	Immune response_Role of integrins in NK cells cytotoxicity ²²	11.4	MAPK1 KLRD1 KLRC1 HLA-E
31	Development and heterogeneity of the ILC family ⁷⁴	11.27	TNF IL6 IL17A
32	Prostaglandin signaling ⁷⁴	11.2	TNF IL6 IL17A
33	Cytokines and inflammatory response ⁷⁴	11.2	TNF IL6 IFNB1 CD4
34	Ebstein-Barr virus LMP1 signaling ⁷⁴	11.1	TNF MAPK1 IFNB1
35	Innate Lymphoid Cells Differentiation ⁶⁵	11	TNF KLRD1 IL17A CD8A CD4 CCR6
36	G-protein signaling_Rap2B regulation pathway ²²	10.97	TNF MAPK1 IL6 IL17A EGFR
37	Cells and molecules involved in local acute inflammatory response ⁷⁴ Show member pathways IL8-mediated signaling events ⁶¹	10.32	TNF IL6

Sources

GO Terms for Human Cytomegalovirus Infection

Cellular components related to Human Cytomegalovirus Infection according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	membrane	GO:0016020	10.33	B3GAT1 CCR6 CD4 CD8A EGFR GYPC
2	membrane	GO:0016021	10.33	B3GAT1 CCR6 CD4 CD8A EGFR GYPC
3	plasma membrane	GO:0005886	10.09	CCR6 CD4 CD8A EGFR GYPC KLRC1
4	plasma membrane	GO:0005887	10.09	CCR6 CD4 CD8A EGFR GYPC KLRC1
5	receptor complex	GO:0043235	9.96	KLRD1 KLRC2 KLRC1 EGFR CD8A
6	external side of plasma membrane	GO:0009897	9.6	TNF LILRB1 KLRD1 KLRC2 KLRC1 IL17A

Biological processes related to Human Cytomegalovirus Infection according to GeneCards Suite gene sharing:

(show all 17)

#	Name	GO ID	Score	Top Affiliating Genes
1	innate immune response	GO:0045087	10.29	HLA-E IL17A KLRC1 KLRC2 KLRD1 PML
2	immune response	GO:0006955	10.21	CCR6 CD4 CD8A HLA-E IL17A IL6
3	cell surface receptor signaling pathway	GO:0007166	10.17	MAPK1 KLRD1 KLRC1 IFNB1 EGFR CD8A
4	defense response to Gram-positive bacterium	GO:0050830	10.15	TNF IL6 IL17A HLA-E
5	defense response to virus	GO:0051607	10.13	RSAD2 PML LILRB1 IL6 IFNB1
6	response to virus	GO:0009615	10.08	TNF RSAD2 LILRB1 IFNB1
7	negative regulation of viral genome replication	GO:0045071	10.04	TNF RSAD2 IFNB1
8	humoral immune response	GO:0006959	10.01	TNF IL6 IFNB1 CCR6
9	positive regulation of cytokine production involved in inflammatory response	GO:1900017	9.97	TNF IL6 IL17A
10	positive regulation of natural killer cell mediated cytotoxicity	GO:0045954	9.95	KLRD1 KLRC2 HLA-E
11	adaptive immune response	GO:0002250	9.89	LILRB1 KLRD1 KLRC2 KLRC1 IL17A IFNB1
12	immune system process	GO:0002376	9.81	RSAD2 PML KLRD1 KLRC2 KLRC1 IL17A
13	negative regulation of T cell mediated cytotoxicity	GO:0001915	9.77	LILRB1 KLRD1 KLRC1
14	natural killer cell mediated immunity	GO:0002228	9.76	KLRD1 KLRC2
15	negative regulation of cytokine production involved in immune response	GO:0002719	9.73	TNF LILRB1
16	regulation of natural killer cell activation	GO:0032814	9.73	KLRC1 KLRC2 KLRD1
17	negative regulation of natural killer cell mediated cytotoxicity	GO:0045953	9.17	LILRB1 KLRD1 KLRC1 HLA-E

Molecular functions related to Human Cytomegalovirus Infection according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	transmembrane signaling receptor activity	GO:0004888	10.02	KLRD1 KLRC2 KLRC1 EGFR CD4
2	MHC class I protein binding	GO:0042288	9.65	LILRB1 HLA-E CD8A
3	HLA-E specific inhibitory MHC class Ib receptor activity	GO:0062082	9.46	KLRD1 KLRC1
4	protein antigen binding	GO:1990405	9.35	KLRD1 KLRC2 KLRC1
5	MHC class I protein complex binding	GO:0023024	9.23	KLRD1 KLRC2 KLRC1 CD8A